Developer docs
API playgroundTry for free, no card

Search company profiles

Medspray

Full company profile

uuid000h4hf

Namestring
Medspray
Legal namestring
Medspray B.V.
Websiteurl
medspray.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Medspray B.V. is a Dutch specialty manufacturer founded in 2002 and headquartered in Enschede, Netherlands, focused on silicon microchip-based spray nozzle technology for the pharmaceutical, consumer health, and beauty markets. The company's core technology consists of spray nozzle units (SNUs) fabricated from silicon wafers using lithography and etching techniques borrowed from semiconductor manufacturing, producing orifices of 1-30 micrometers that generate mono-disperse fine mist aerosols via the Rayleigh jet principle at production rates of approximately 2,400 SNUs per hour in ISO 8 cleanrooms. This engineering approach delivers quantitative performance advantages including 3-4x higher lung deposition versus conventional pressurized metered-dose and dry powder inhalers, greater than 50% lung dose of metered dose in the pre-filled syringe inhaler (PFSI) platform, 50x lower energy consumption than classical nebulizers, and roughly 10x less degradation of biological active ingredients during nebulization.

The product portfolio spans pharmaceutical soft mist inhalers (Ecomyst90, Soft Breezer, PFSI, Pulmospray), nasal delivery devices (Nasal Atomiser Adapter, multi-dose soft mist nasal spray), the Trachospray local anesthesia device for upper airway procedures, preservative-free ophthalmic sprays, and the Silk fine fragrance system. Six patent families protect the underlying technology and ISO 13485 certification has been maintained since 2010. The company is structured under five wholly-owned subsidiaries (Medspray Pharma B.V., Medspray Non-Pharma B.V., Medspray Technology & Manufacturing B.V., Medspray Anesthesia B.V., Medspray Mystic B.V.) plus a 49% stake in the Resyca joint venture with Recipharm (established 2020, EUR 15 million investment) which commercializes soft mist inhaler platforms for pharmaceutical and biologic customers.

Medspray operates a hybrid B2B revenue model combining direct sales of SNUs and custom device development services, an OEM/licensing model in which its nozzle technology is embedded inside partner-branded products such as Aptar Pharma's PureHale and Aptar Beauty & Home's Silk, and royalty/equity participation through the Resyca JV. Customers span pharmaceutical companies (prescription and OTC drug delivery), consumer health brands (nasal, eye, cough/cold, skin care), beauty and home care companies (fine fragrances and deodorants), medical device partners (respiratory humidification, anesthesia), and public health programs (Bill & Melinda Gates Foundation-funded nebulizer for premature infant respiratory distress syndrome). The company maintains enterprise sales through email and direct contact, with a 40-person operating team as of late 2023.

Short descriptiontext

Medspray B.V. is a Dutch manufacturer of silicon microchip spray nozzle technology serving pharmaceutical, consumer health, and beauty brands with propellant-free, mono-disperse soft mist inhaler and spray device platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEnschede, Netherlands
HQ citystring
Enschede
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spray nozzle technology, soft mist inhalers, drug delivery devices, propellant-free aerosols, microchip nozzles
Industry4 codes
PRIMARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYIMALALAE
Trigger Sprayers & Mist Sprayers
SECONDARYCRABADAC
Body Sprays & Mists
SECONDARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Medical Device Components / Drug Delivery Technology
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Spray Nozzle Unit (SNU) Sales
TypeHardware Sales
Description

Manufacturing and selling spray nozzle units to pharmaceutical and consumer product companies. Units produced from silicon wafers in batch processes.

medspray.com
2Licensing of Technology
TypeLicensing Royalties
Description

Licensing Medspray's patented spray nozzle technology to partners for integration into their products (e.g., Aptar for PureHale and Silk, Aero Pump for Ecomyst90).

medspray.com
3Custom Device Development
TypeProfessional Services
Description

Developing customized inhaler and spray devices for specific pharmaceutical and consumer health applications, often in collaboration with partners.

medspray.com
4Resyca Joint Venture Revenue
TypeLicensing Royalties
Description

Through 49% owned joint venture Resyca with Recipharm, generating revenue from pharmaceutical soft mist inhaler development and manufacturing.

medspray.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Infrastructure, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Resyca
Description

Joint venture with Recipharm developing soft mist inhalers based on pre-filled syringes and Medspray's nozzle technology for pharma and biologic customers

medspray.com
+3 more records
Core offering1 text field

Medspray designs and manufactures silicon-based micro- and nano-technology spray nozzle units (SNUs) that generate propellant-free mono-disperse fine mist sprays. The nozzles are produced from silicon wafers using lithography and etching techniques from semiconductor manufacturing, with orifice sizes of 1-30 micrometers. The company sells these nozzles and integrated soft mist inhaler, nasal, ocular, and fragrance delivery devices to pharmaceutical companies, consumer health brands, and beauty/home care manufacturers under OEM/embedded and licensing models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Lung dose 3-4x larger than conventional pMDIs or dry powder inhalers
+4 more records
Product overview1 text field

Medspray is a spray nozzle technology company offering a portfolio of soft mist inhaler devices and spray products across pharma, consumer health, and beauty sectors. The core technology consists of micro and nano-technology based spray nozzle units (SNUs) that create fine mist sprays without propellants. Key products include soft mist inhalers for respiratory conditions (Ecomyst90, Soft Breezer, PFSI inhaler, Pulmospray), nasal delivery devices (Nasal Atomiser Adapter, Nasal Spray), anesthesia devices (Trachospray), ophthalmic products (Eye Spray), and fragrance systems (Silk). The company also develops respiratory humidification technology. Medspray's nozzles produce mono-disperse droplets (4µm with 2µm hole) and are manufactured using silicon chip technology with orifices of 1-30 micrometers.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership19 partners
1Recipharm
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-17
Description

Joint venture Resyca established with Recipharm investing EUR 15 million for 51% of shares. Medspray transfers softmist IP relating to pharmaceutical applications to Resyca. Resyca operates development facilities in Munich and manufacturing via Recipharm affiliates including King's Lynn, UK.

medspray.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture between Medspray and Recipharm combining spray nozzle technology with pharmaceutical device expertise. Medspray supplies nozzles exclusively to Resyca.

3Trachospray / Medspray Anesthesia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Medspray Anesthesia is a spin-off from Medspray, developing and supplying the Trachospray microdroplet spray device for local anesthesia. CE marked and available to medical professionals in EU.

medspray.com
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Aptar Pharma's PureHale device uses Medspray's nozzle technology for upper airway condition relief products. PureHale uses Bag-on-Valve technology with compressed air.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Partnership with Aptar Beauty & Home combining their dispensing systems knowledge with Medspray's spray technology to create Silk - ultimate refined fragrance spray.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Joint development of Ecomyst90 soft mist inhaler and Soft breezer device combining Aero Pump's pump system with Medspray's nozzle technology.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Clinical partnership for Trachospray development. Prof. dr Jörgen Bruhn and dr. Geert-Jan van Geffen invented the concept. Radboud umc ran clinical trials validating safety and efficacy.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Surterra Wellness distributes Ecomyst90 CBD inhaler in US market. Their subsidiary Molecular Infusions developed the CBD formulation optimized for Medspray's soft mist inhaler device.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Daughter company Resyca supplied Pulmospray soft mist inhalation devices for Phase IIb clinical trial of COVID-19 induced hypoxemia treatment with low molecular weight Heparin.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partnership to develop innovative active humidifier controlling absolute humidity instead of relative humidity for improved respiratory care and medication delivery efficiency.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partnership with PCV Group and Unitron to develop active humidifier technology for respiratory care with focus on absolute humidity control.

12ProfTech
Strategic tierMinorTypeStrategic or Co-development Partner
Description

VIVA project partner alongside Medspray and Saxion University developing image-driven inspection system for micro-fluidic chip assembly quality control.

medspray.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

VIVA project partner alongside Medspray and ProfTech developing image-driven inspection system for micro-fluidic chip assembly quality control.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Eurostars Grant collaboration for development of antimicrobial spray for wound care using Amferia's antimicrobial peptide-hydrogel materials with Medspray's spray technology.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Exclusive license agreement for Medspray's soft mist nasal spray technology for use with SPC-15 therapeutic drug for PTSD, anxiety, Alzheimer's disease, and anorexia treatment.

16Royal Netherlands Aerospace Centre (NLR)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Provided expertise and equipment for COVID-19 research on aerosol spreading behavior in airplane cabins.

medspray.com
17Dutch National Institute for Public Health and the Environment (RIVM)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborated on COVID-19 aerosol research validating models for infection risk during airplane flights.

medspray.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

R&D operations conducted at extensive Nanolab facilities of Twente University where operators create silicon nozzle chips for research purposes.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Prototypes being tested at Seattle Children's Hospital to validate nebulization technique for liquid surfactants for premature infant treatment.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Inhalation drug delivery specialist developing DPI and pMDI platforms for pharma partners. Operates in overlapping soft mist and propellant-free inhaler licensing territory where Medspray competes.

TypeDirect peer
Description

Global drug delivery device company serving pharma and consumer health. Directly comparable because Aptar Pharma partners with Medspray to embed its nozzle chip in PureHale and Silk devices, competing in pMDI, soft mist, nasal, and topical spray platforms.

3Recipharm
TypeDirect peer
Description

Pharmaceutical contract development and manufacturing organization. Recipharm co-owns the Resyca JV with Medspray (51%/49%) for soft mist inhaler development and fill-finish services, operating in the same pharmaceutical device and inhalation therapy value chain.

TypeDirect peer
Description

German specialty pump and inhaler manufacturer. Aero Pump combines its pump systems with Medspray's nozzle technology in Ecomyst90 and Soft Breezer soft mist inhalers, directly competing in propellant-free multi-dose inhalers.

TypeDirect peer
Description

Drug delivery device company specializing in inhalers, nasal, ophthalmic, and parenteral devices. Nemera competes directly in soft mist and nasal spray device platforms with equivalent regulatory and OEM partnerships.

TypeDirect peer
Description

Manufacturer of nebulizers and inhalation drug delivery systems. PARI's eFlow and LC Sprint jet nebulizers compete with Medspray's Pulmospray and PFSI platforms for pulmonary drug delivery, particularly in hospital and home-care settings.

TypeEmerging player
Description

Taipei-based developer of mesh nebulizer and portable drug delivery technology. Competes in portable inhalation drug delivery with its own MEMS-driven mesh nebulizer platform overlapping with Medspray's soft mist inhaler use cases.

TypeBroad incumbent
Description

Global manufacturer of pharmaceutical primary packaging including glass syringes, plastic containers and inhaler components. Provides adjacent drug delivery components relevant to Medspray's PFSI pre-filled syringe inhaler platform.

TypeBroad incumbent
Description

Provider of drug containment and delivery solutions including pre-filled syringes and device integration. Its pharma device platform competes in adjacent delivery systems relevant to Medspray's syringe-based inhaler.

TypeDirect peer
Description

Joint venture between Medspray (49%) and Recipharm (51%) developing soft mist inhalers based on pre-filled syringes. Medspray supplies nozzle technology exclusively to Resyca, creating an internal commercial arm that competes with established inhaler CDMOs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medspray

Medical Device Components / Drug Delivery Technologymedspray.com

Medspray B.V. is a Dutch manufacturer of silicon microchip spray nozzle technology serving pharmaceutical, consumer health, and beauty brands with propellant-free, mono-disperse soft mist inhaler and spray device platforms.

What Medspray does

Medspray B.V. is a Dutch specialty manufacturer founded in 2002 and headquartered in Enschede, Netherlands, focused on silicon microchip-based spray nozzle technology for the pharmaceutical, consumer health, and beauty markets. The company's core technology consists of spray nozzle units (SNUs) fabricated from silicon wafers using lithography and etching techniques borrowed from semiconductor manufacturing, producing orifices of 1-30 micrometers that generate mono-disperse fine mist aerosols via the Rayleigh jet principle at production rates of approximately 2,400 SNUs per hour in ISO 8 cleanrooms. This engineering approach delivers quantitative performance advantages including 3-4x higher lung deposition versus conventional pressurized metered-dose and dry powder inhalers, greater than 50% lung dose of metered dose in the pre-filled syringe inhaler (PFSI) platform, 50x lower energy consumption than classical nebulizers, and roughly 10x less degradation of biological active ingredients during nebulization.

The product portfolio spans pharmaceutical soft mist inhalers (Ecomyst90, Soft Breezer, PFSI, Pulmospray), nasal delivery devices (Nasal Atomiser Adapter, multi-dose soft mist nasal spray), the Trachospray local anesthesia device for upper airway procedures, preservative-free ophthalmic sprays, and the Silk fine fragrance system. Six patent families protect the underlying technology and ISO 13485 certification has been maintained since 2010. The company is structured under five wholly-owned subsidiaries (Medspray Pharma B.V., Medspray Non-Pharma B.V., Medspray Technology & Manufacturing B.V., Medspray Anesthesia B.V., Medspray Mystic B.V.) plus a 49% stake in the Resyca joint venture with Recipharm (established 2020, EUR 15 million investment) which commercializes soft mist inhaler platforms for pharmaceutical and biologic customers.

Medspray operates a hybrid B2B revenue model combining direct sales of SNUs and custom device development services, an OEM/licensing model in which its nozzle technology is embedded inside partner-branded products such as Aptar Pharma's PureHale and Aptar Beauty & Home's Silk, and royalty/equity participation through the Resyca JV. Customers span pharmaceutical companies (prescription and OTC drug delivery), consumer health brands (nasal, eye, cough/cold, skin care), beauty and home care companies (fine fragrances and deodorants), medical device partners (respiratory humidification, anesthesia), and public health programs (Bill & Melinda Gates Foundation-funded nebulizer for premature infant respiratory distress syndrome). The company maintains enterprise sales through email and direct contact, with a 40-person operating team as of late 2023.

Medspray firmographics

Firmographics
Name
Medspray
Legal name
Medspray B.V.
Website
https://medspray.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
Medspray B.V. is a Dutch manufacturer of silicon microchip spray nozzle technology serving pharmaceutical, consumer health, and beauty brands with propellant-free, mono-disperse soft mist inhaler and spray device platforms.
Ownership category
akta.pro rank

Medspray industry classification

Industry
Product category
Medical Device Components / Drug Delivery Technology
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYIMALALAE
Trigger Sprayers & Mist Sprayers
SECONDARYCRABADAC
Body Sprays & Mists
SECONDARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Spray nozzle technology
  • Soft mist inhalers
  • Drug delivery devices
  • Propellant-free aerosols
  • Microchip nozzles

Where Medspray is headquartered

Location

Headquarters

HQ city
Enschede
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Medspray business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Infrastructure, Personnel, Marketing or Sales

Revenue model

  1. Spray Nozzle Unit (SNU) Sales: Manufacturing and selling spray nozzle units to pharmaceutical and consumer product companies. Units produced from silicon wafers in batch processes.
  2. Licensing of Technology: Licensing Medspray's patented spray nozzle technology to partners for integration into their products (e.g., Aptar for PureHale and Silk, Aero Pump for Ecomyst90).
  3. Custom Device Development: Developing customized inhaler and spray devices for specific pharmaceutical and consumer health applications, often in collaboration with partners.
  4. Resyca Joint Venture Revenue: Through 49% owned joint venture Resyca with Recipharm, generating revenue from pharmaceutical soft mist inhaler development and manufacturing.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Medspray product offering

Product offering

Core offering

Medspray designs and manufactures silicon-based micro- and nano-technology spray nozzle units (SNUs) that generate propellant-free mono-disperse fine mist sprays. The nozzles are produced from silicon wafers using lithography and etching techniques from semiconductor manufacturing, with orifice sizes of 1-30 micrometers. The company sells these nozzles and integrated soft mist inhaler, nasal, ocular, and fragrance delivery devices to pharmaceutical companies, consumer health brands, and beauty/home care manufacturers under OEM/embedded and licensing models.

Product overview

Medspray is a spray nozzle technology company offering a portfolio of soft mist inhaler devices and spray products across pharma, consumer health, and beauty sectors. The core technology consists of micro and nano-technology based spray nozzle units (SNUs) that create fine mist sprays without propellants. Key products include soft mist inhalers for respiratory conditions (Ecomyst90, Soft Breezer, PFSI inhaler, Pulmospray), nasal delivery devices (Nasal Atomiser Adapter, Nasal Spray), anesthesia devices (Trachospray), ophthalmic products (Eye Spray), and fragrance systems (Silk). The company also develops respiratory humidification technology. Medspray's nozzles produce mono-disperse droplets (4µm with 2µm hole) and are manufactured using silicon chip technology with orifices of 1-30 micrometers.

Differentiator

Problem solved

Functional benefit

Brands

  • Resyca: Joint venture with Recipharm developing soft mist inhalers based on pre-filled syringes and Medspray's nozzle technology for pharma and biologic customers
  • Trachospray
  • Ecomyst90
  • Silk

Quantifiable outcome

  • Lung dose 3-4x larger than conventional pMDIs or dry powder inhalers
  • +4 more outcomes

Companies that use Medspray

Customer profile

Named customers11 records

Segments3 records

Ideal customer profiles4 records

Medspray technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Medspray partnerships and signals

Strategic signal

Partnerships

19 partnerships are on record, tiered core, major and minor.

  • RecipharmcoreStrategic or Co-development Partner · 17 November 2020Joint venture Resyca established with Recipharm investing EUR 15 million for 51% of shares. Medspray transfers softmist IP relating to pharmaceutical applications to Resyca. Resyca operates development facilities in Munich and manufacturing via Recipharm affiliates including King's Lynn, UK.
  • ResycacoreStrategic or Co-development PartnerJoint venture between Medspray and Recipharm combining spray nozzle technology with pharmaceutical device expertise. Medspray supplies nozzles exclusively to Resyca.
  • Trachospray / Medspray AnesthesiacoreStrategic or Co-development PartnerMedspray Anesthesia is a spin-off from Medspray, developing and supplying the Trachospray microdroplet spray device for local anesthesia. CE marked and available to medical professionals in EU.
  • Aptar PharmamajorOEM/ Whitelabel/ Licensing PartnerAptar Pharma's PureHale device uses Medspray's nozzle technology for upper airway condition relief products. PureHale uses Bag-on-Valve technology with compressed air.
  • Aptar Beauty & HomemajorOEM/ Whitelabel/ Licensing PartnerPartnership with Aptar Beauty & Home combining their dispensing systems knowledge with Medspray's spray technology to create Silk - ultimate refined fragrance spray.
  • Aero PumpmajorOEM/ Whitelabel/ Licensing PartnerJoint development of Ecomyst90 soft mist inhaler and Soft breezer device combining Aero Pump's pump system with Medspray's nozzle technology.
  • Radboud University Medical CentermajorStrategic or Co-development PartnerClinical partnership for Trachospray development. Prof. dr Jörgen Bruhn and dr. Geert-Jan van Geffen invented the concept. Radboud umc ran clinical trials validating safety and efficacy.
  • Surterra WellnessmajorChannel Partner/ Reseller/ DistributorSurterra Wellness distributes Ecomyst90 CBD inhaler in US market. Their subsidiary Molecular Infusions developed the CBD formulation optimized for Medspray's soft mist inhaler device.
  • ResycacoreStrategic or Co-development PartnerDaughter company Resyca supplied Pulmospray soft mist inhalation devices for Phase IIb clinical trial of COVID-19 induced hypoxemia treatment with low molecular weight Heparin.
  • PCV GroupmajorStrategic or Co-development PartnerPartnership to develop innovative active humidifier controlling absolute humidity instead of relative humidity for improved respiratory care and medication delivery efficiency.
  • UnitronmajorStrategic or Co-development PartnerPartnership with PCV Group and Unitron to develop active humidifier technology for respiratory care with focus on absolute humidity control.
  • ProfTechminorStrategic or Co-development PartnerVIVA project partner alongside Medspray and Saxion University developing image-driven inspection system for micro-fluidic chip assembly quality control.
  • Saxion University of Applied SciencesminorStrategic or Co-development PartnerVIVA project partner alongside Medspray and ProfTech developing image-driven inspection system for micro-fluidic chip assembly quality control.
  • AmferiaminorStrategic or Co-development PartnerEurostars Grant collaboration for development of antimicrobial spray for wound care using Amferia's antimicrobial peptide-hydrogel materials with Medspray's spray technology.
  • Silo PharmamajorOEM/ Whitelabel/ Licensing PartnerExclusive license agreement for Medspray's soft mist nasal spray technology for use with SPC-15 therapeutic drug for PTSD, anxiety, Alzheimer's disease, and anorexia treatment.
  • Royal Netherlands Aerospace Centre (NLR)minorStrategic or Co-development PartnerProvided expertise and equipment for COVID-19 research on aerosol spreading behavior in airplane cabins.
  • Dutch National Institute for Public Health and the Environment (RIVM)minorStrategic or Co-development PartnerCollaborated on COVID-19 aerosol research validating models for infection risk during airplane flights.
  • Twente UniversityminorStrategic or Co-development PartnerR&D operations conducted at extensive Nanolab facilities of Twente University where operators create silicon nozzle chips for research purposes.
  • Seattle Children's HospitalminorStrategic or Co-development PartnerPrototypes being tested at Seattle Children's Hospital to validate nebulization technique for liquid surfactants for premature infant treatment.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Medspray competitors and assessment

Company assessment

Direct peers

  • Vectura Group (Kindeva Drug Delivery): Inhalation drug delivery specialist developing DPI and pMDI platforms for pharma partners. Operates in overlapping soft mist and propellant-free inhaler licensing territory where Medspray competes.
  • Aptar Pharma: Global drug delivery device company serving pharma and consumer health. Directly comparable because Aptar Pharma partners with Medspray to embed its nozzle chip in PureHale and Silk devices, competing in pMDI, soft mist, nasal, and topical spray platforms.
  • Recipharm: Pharmaceutical contract development and manufacturing organization. Recipharm co-owns the Resyca JV with Medspray (51%/49%) for soft mist inhaler development and fill-finish services, operating in the same pharmaceutical device and inhalation therapy value chain.
  • Aero Pump: German specialty pump and inhaler manufacturer. Aero Pump combines its pump systems with Medspray's nozzle technology in Ecomyst90 and Soft Breezer soft mist inhalers, directly competing in propellant-free multi-dose inhalers.
  • Nemera: Drug delivery device company specializing in inhalers, nasal, ophthalmic, and parenteral devices. Nemera competes directly in soft mist and nasal spray device platforms with equivalent regulatory and OEM partnerships.
  • PARI Pharma: Manufacturer of nebulizers and inhalation drug delivery systems. PARI's eFlow and LC Sprint jet nebulizers compete with Medspray's Pulmospray and PFSI platforms for pulmonary drug delivery, particularly in hospital and home-care settings.
  • Resyca: Joint venture between Medspray (49%) and Recipharm (51%) developing soft mist inhalers based on pre-filled syringes. Medspray supplies nozzle technology exclusively to Resyca, creating an internal commercial arm that competes with established inhaler CDMOs.

Emerging players

  • HCmed Innovations: Taipei-based developer of mesh nebulizer and portable drug delivery technology. Competes in portable inhalation drug delivery with its own MEMS-driven mesh nebulizer platform overlapping with Medspray's soft mist inhaler use cases.

Broad incumbents

  • Gerresheimer: Global manufacturer of pharmaceutical primary packaging including glass syringes, plastic containers and inhaler components. Provides adjacent drug delivery components relevant to Medspray's PFSI pre-filled syringe inhaler platform.
  • Stevanato Group: Provider of drug containment and delivery solutions including pre-filled syringes and device integration. Its pharma device platform competes in adjacent delivery systems relevant to Medspray's syringe-based inhaler.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Medspray social profiles

Digital presence

Medspray compliance and trust

Trust signal

Compliance3 records

Medspray financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medspray leadership team

Management profile

Number of profiles

Profiles3 records

Medspray subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Medspray funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medspray M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medspray

What does Medspray do?

Medspray designs and manufactures silicon-based micro- and nano-technology spray nozzle units (SNUs) that generate propellant-free mono-disperse fine mist sprays. The nozzles are produced from silicon wafers using lithography and etching techniques from semiconductor manufacturing, with orifice sizes of 1-30 micrometers. The company sells these nozzles and integrated soft mist inhaler, nasal, ocular, and fragrance delivery devices to pharmaceutical companies, consumer health brands, and beauty/home care manufacturers under OEM/embedded and licensing models.

Is Medspray a public or private company?

Medspray is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Medspray founded?

Medspray was founded in 2002. It employs 11 to 50 people.

Where is Medspray based?

Medspray is headquartered in Enschede, Netherlands, in the Europe region.

How does Medspray make money?

Four revenue lines are on record. Spray Nozzle Unit (SNU) Sales are the primary driver. The others are licensing of Technology, custom Device Development and resyca Joint Venture Revenue.

Who are Medspray's main competitors?

Direct peers on record are Vectura Group (Kindeva Drug Delivery), Aptar Pharma, Recipharm, Aero Pump, Nemera, PARI Pharma and Resyca. HCmed Innovations is listed as an emerging player. Broad incumbents are Gerresheimer and Stevanato Group.

Does Medspray have an API?

No public API is recorded for Medspray.

What industry is Medspray in?

Medspray's product category is Medical Device Components / Drug Delivery Technology. Its primary akta.pro industry code is HLAHAIAI, Inhalers (MDI/DPI/SMI), with a secondary code of IMALALAE, Trigger Sprayers & Mist Sprayers. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ContractpharmaRecipharm Enters License & Collaboration Agreement with Medspray and ResycaRecipharm signed an exclusive license and collaboration agreement with Medspray and Resyca to develop soft mist nasal delivery devices. Resyca gains exclusive rights to Medspray's spray nozzle technology for nasal devices and combination drug products. The companies anticipate breakthroughs in nasal delivery of fragile biological formulations, such as mRNA vaccines.GlobeNewswireSilo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSDSilo Pharma announced an exclusive license agreement with Medspray Pharma BV for its patented soft mist nasal spray technology, selected for its intranasal drug SPC-15. The agreement covers multiple indications including PTSD, anxiety, Alzheimer's disease, and anorexia. SPC-15, a serotonin 4 receptor agonist, is being developed for PTSD and other stress-induced disorders.BenzingaSilo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder Candidate - SSilo Pharma Inc announced an exclusive license agreement with Medspray Pharma BV to use its patented soft mist nasal spray technology as the delivery mechanism for SPC-15, an intranasal therapeutic drug candidate being developed for PTSD, anxiety, Alzheimer's disease, and anorexia. SPC-15 is a serotonin 4 (5-HT4) receptor agonist currently in preclinical studies being conducted in collaboration with Columbia University. If clinically successful, SPC-15 could qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval.news.cision.comRecipharm and Medspray launch Resyca joint venture to exploit novel softmist technology for pharmaceutical applicationsRecipharm and Medspray completed their joint venture, establishing Resyca BV to develop softmist spray nozzle technology for pharmaceutical applications. The technology aims to eliminate propellants and deliver therapies with lower doses, with development facilities in Munich and nozzle supply from Medspray in the Netherlands.